Is raising HDL a futile strategy for atheroprotection?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,General Medicine
Link
http://www.nature.com/articles/nrd2489.pdf
Reference158 articles.
1. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007). This randomized trial showed that among individuals at high risk of cardiovascular disease, treatment with torcetrapib (60 mg/day) plus atorvastatin (10–80 mg/day) versus atorvastatin alone was associated with an increased risk of cardiovascular events despite a 72% increase in HDL-C and 25% decrease in LDL-C levels.
2. Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007). This randomized trial showed that despite a 61% increase in HDL-C and a 20% decrease in LDL-C, torcetrapib in combination with atorvastatin versus atorvastatin alone did not significantly decrease the progression of coronary atherosclerosis among 1,188 patients with CHD.
3. Kastelein, J. J. et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620–1630 (2007). Compared to atorvastatin therapy alone, the combination of torcetrapib with atorvastatin did not further reduce carotid atherosclerosis but was associated with progression of atherosclerosis in the common carotid segment among 850 patients with heterozygous familial hypercholesterolaemia, despite a significant 50% elevation in HDL-C levels.
4. Bots, M. L. et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370, 153–160 (2007). Torcetrapib in combination with atorvastatin versus atorvastatin alone did not affect carotid atherosclerosis progression despite a 63% increase in HDL-C and 18% decrease in LDL-C.
5. Singh, I. M., Shishehbor, M. H. & Ansell, B. J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298, 786–798 (2007). An excellent systematic review outlining the clinical evidence of HDL-raising and atherosclerosis.
Cited by 126 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease;Journal of Clinical Lipidology;2024-09
2. Bisdemethoxycurcumin suppresses the progression of atherosclerosis and VSMC-derived foam cell formation by promoting lipophagy;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-06-08
3. Bound Phospholipids Assist Cholesteryl Ester Transfer in the Cholesteryl Ester Transfer Protein;Journal of Chemical Information and Modeling;2023-05-10
4. HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS;International Journal of Molecular Sciences;2023-03-11
5. Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARα/γ partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and improves glucose tolerance in diet-induced obese mice;Bioorganic Chemistry;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3